The combination of HE4 and CA125, when used in the Risk of Ovarian Malignancy Algorithm (ROMA) test, is effective at classifying women presenting with a pelvic mass into high- or low-risk categories, which enables the triage of women likely to have ovarian cancer to clinical settings and surgeons with appropriate expertise [7, 8]. This evidence concerns the gene WFDC2 and ovarian cancer.